Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.

Autor: Roloff GW; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Aldoss I; Division of Leukemia, Department of Hematology and Hematopoitic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Kopmar NE; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Lin C; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC., Dekker SE; Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Gupta VK; Division of Hematology & Oncology, University of California Los Angeles, Los Angeles, CA., O'Connor TE; Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL., Jeyakumar N; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Muhsen IN; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX., Valtis Y; Memorial Sloan Kettering Cancer Center, New York, NY., Ahmed N; Memorial Sloan Kettering Cancer Center, New York, NY., Zhang A; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Miller K; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Dykes KC; Department of Medicine, Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, CA., Ahmed M; Cedars-Sinai Medical Center, Los Angeles, CA., Chen EC; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Mercadal S; Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Schwartz M; University of Colorado Anschutz School of Medicine, Aurora, CO., Tracy SI; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Dholaria B; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Mukherjee A; University of Arkansas Medical Center, Little Rock, AK., Battiwalla M; Sarah Cannon Transplant and Cell Therapy Network, Nashville, TN., Logan AC; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA., Ladha A; Department of Hematology, Norris Cancer Center, University of Southern California, Los Angeles, CA., Guzowski C; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Hoeg RT; Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA., Hilal T; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ., Moore J; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY., Connor MP; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Hill LC; Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital, Houston, TX., Tsai SB; Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL., Sasine JP; Cedars-Sinai Medical Center, Los Angeles, CA., Solh MM; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Kota VK; Georgia Cancer Center, Augusta University, Augusta, GA., Koura D; Department of Medicine, Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, CA., Veeraputhiran M; University of Arkansas Medical Center, Little Rock, AK., Leonard JT; Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Frey NV; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Park JH; Memorial Sloan Kettering Cancer Center, New York, NY., Luskin MR; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Bachanova V; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Galal A; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC., Pullarkat V; Division of Leukemia, Department of Hematology and Hematopoitic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Stock W; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Cassaday RD; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Shah BD; Moffitt Cancer Center, Tampa, FL., Faramand R; Moffitt Cancer Center, Tampa, FL., Muffly L; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 17, pp. JCO2400321. Date of Electronic Publication: 2024 Oct 17.

Epidermal growth factor augments the self-renewal capacity of aged hematopoietic stem cells.

Autor: Chang VY; Division of Hematology-Oncology, Department of Pediatrics, UCLA, Los Angeles, CA, USA.; Children's Discovery and Innovation Institute, UCLA, Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA., He Y; Division of Hematology & Cellular Therapy, Cedars Sinai Medical Center, Los Angeles, CA, USA., Grohe S; Division of Hematology & Cellular Therapy, Cedars Sinai Medical Center, Los Angeles, CA, USA., Brady MR; Division of Hematology & Cellular Therapy, Cedars Sinai Medical Center, Los Angeles, CA, USA., Chan A; Division of Hematology & Cellular Therapy, Cedars Sinai Medical Center, Los Angeles, CA, USA., Kadam RS; Division of Hematology & Cellular Therapy, Cedars Sinai Medical Center, Los Angeles, CA, USA., Fang T; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, USA., Pang A; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Pohl K; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Tran E; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Li M; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Kan J; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Zhang Y; Molecular Biology Institute, UCLA, Los Angeles, CA 90095, USA., Lu JJ; Applied Genomics, Computation and Translational Core, Cedars Sinai Medical Center, Los Angeles, CA, USA., Sasine JP; Division of Hematology & Cellular Therapy, Cedars Sinai Medical Center, Los Angeles, CA, USA., Himburg HA; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Yue P; Division of Hematology & Cellular Therapy, Cedars Sinai Medical Center, Los Angeles, CA, USA., Chute JP; Division of Hematology & Cellular Therapy, Cedars Sinai Medical Center, Los Angeles, CA, USA.; Board of Governors Regenerative Medicine Institute, Cedars Sinai Medical Center, Los Angeles, CA 90095, USA.; Samuel Oschin Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90095, USA.; Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 91361, USA.

Publikováno v: IScience [iScience] 2024 Jun 19; Vol. 27 (7), pp. 110306. Date of Electronic Publication: 2024 Jun 19 (Print Publication: 2024).

IMAGE-seq and you shall find.

Autor: Chute JP; Division of Hematology & Cellular Therapy, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA. john.chute@cshs.org.; Regenerative Medicine Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA. john.chute@cshs.org.; Samuel Oschin Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA. john.chute@cshs.org., Sasine JP; Division of Hematology & Cellular Therapy, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.; Regenerative Medicine Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.; Samuel Oschin Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.

Publikováno v: Nature methods [Nat Methods] 2023 May; Vol. 20 (5), pp. 639-640.

Diminished durability of chimeric antigen receptor T-cell efficacy with severe or prolonged postinfusion cytopenias.

Autor: Tabbara N; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Sharp J; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Gaut D; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Pham TTD; Molecular, Cellular, and Integrative Physiology, University of California Los Angeles, Los Angeles, California, USA., Tang K; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Oliai C; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Sim MS; Division of General Internal Medicine and Health Services Research, Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Schiller G; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Young P; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Sasine JP; Division of Hematology and Cellular Therapy, Department of Medicine, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2022 Jul; Vol. 97 (7), pp. E249-E255. Date of Electronic Publication: 2022 Apr 11.

Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.

Autor: Li YR; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Zhou Y; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Kim YJ; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Zhu Y; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Ma F; Department of Molecular, Cell and Developmental Biology, College of Letters and Sciences, University of California, Los Angeles, Los Angeles, CA 90095, USA., Yu J; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Wang YC; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Chen X; Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA., Li Z; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Zeng S; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Wang X; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Lee D; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Ku J; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Tsao T; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Hardoy C; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Huang J; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Cheng D; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA., Montel-Hagen A; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., Seet CS; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., Crooks GM; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Department of Pediatrics, University of California, Los Angeles, Los Angeles, CA 90095, USA., Larson SM; Department of Internal Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., Sasine JP; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Division of Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., Wang X; Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., Pellegrini M; Department of Molecular, Cell and Developmental Biology, College of Letters and Sciences, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA., Ribas A; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Parker Institute for Cancer Immunotherapy, University of California, Los Angeles, Los Angeles, CA 90095, USA., Kohn DB; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Division of Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., Witte O; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Parker Institute for Cancer Immunotherapy, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA., Wang P; Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA., Yang L; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2021 Nov 16; Vol. 2 (11), pp. 100449. Date of Electronic Publication: 2021 Nov 16 (Print Publication: 2021).